Abstract
The ATTRACTION-2 trial demonstrated the survival benefits of nivolumab in heavily treated advanced gastric cancer. Moreover, nivolumab has been approved for third- or later line treatment regardless of the human epidermal growth factor receptor 2 (HER2) status. However, there is limited information about variations in the efficacy of nivolumab according to the HER2 status. This study aimed to assess the differences in the efficacy of nivolumab between HER2-positive and -negative population for advanced gastric cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
